Background: Genome-wide association studies (GWAS) have identified more than 100 genetic loci for various cancers. However, only one is for endometrial cancer.
Introduction
Endometrial cancer is the second most common gynecologic cancer in the world (1) . Early age at menarche, late age at menopause, nulliparity, obesity, use of estrogenalone hormone replacement therapy, use of tamoxifen, and family history of endometrial, breast, ovarian, or colorectal cancer are established risk factors for endometrial cancer (2) . Over the past 10 years, a number of studies have reported that certain genetic variants are associated with endometrial cancer risk, including polymorphisms in genes involved in estrogen metabolism (3) . However, very few of these associations have been confirmed (4) (5) (6) (7) . Given that almost all previous studies used the candidate gene approach, in which only a limited number of genetic variants are investigated, and the choice of genes is driven by our limited knowledge of cancer biology, more comprehensive genetic investigations of endometrial cancer risk are urgently needed. Genome-wide association studies (GWAS) have successfully identified more than 100 genetic loci at P < 5 Â 10 À8 for common cancers (8) . Many GWAS-identified markers are located in genes or nongene regions that had not previously been associated with cancer susceptibility. Very recently, the first endometrial cancer GWAS, conducted by Spurdle and colleagues (9) , reported a novel endometrial cancer susceptibility marker, rs4430796. This marker is located on chromosome 17q, very close to the HNF1B gene, and has also been associated with an increased risk of prostate cancer (10, 11) and decreased risk of type II diabetes (12) . To identify additional endometrial cancer risk variants, we conducted a 3-stage GWAS among 24,071 patients with endometrial cancer and controls.
Materials and Methods
An overview of the study design, including study stage, study population, and single-nucleotide polymorphism (SNP) selection, are presented in Fig. 1 .
Study population
Fourteen studies contributed a total of 8,492 endometrial cancer cases and 16,596 controls to this study. Table S1 ).
The study protocol was approved by the Institutional Review Boards at Vanderbilt University Medical Center (Nashville, TN) and each of the collaborating institutes. Informed consent was obtained from all participants.
Stage I genotyping
Genotyping was conducted by the Affymetrix GenomeWide Human SNP Array 6.0. All genotyping protocols and quality control (QC) procedures were identical to those used in our breast cancer GWAS (13) . We included one negative and 3 positive QC samples from Coriell Cell Repositories (14) in each of the 96-well plates for GWAS genotyping. The average concordance rate among QC samples was 99.85% with a median value of 100%. The sex of all study samples was confirmed to be female. 
2).
Stage II genotyping Methods have been described in detail elsewhere (9) . In brief, endometrioid endometrial cancer subtype cases were genotyped by the Illumina Human 610K array; control data were extracted for these 610K SNPs from existing Illumina 1.2M genome-wide scan data for the WTCCC2 (16) . Of the top 106 SNPs selected from the current stage I, data were available for 99 SNPs in the stage II data set, including 27 directly genotyped SNPs and 72 surrogate SNPs (Supplementary Table S2 ; imputation data were not available at the time of study implementation). Surrogate SNPs were selected on the basis of the following criteria: (i) data available in stage II; (ii) in LD with the index SNP (r 2 > 0.5 in Caucasians); (iii) if multiple SNPs were in LD with the index SNP, the SNP with the strongest LD with the index SNP was selected; and (iv) if multiple SNPs in similar LD with the index SNP in Caucasians, the SNP with the strongest LD in Asians was selected.
Stage III SNP selection and genotyping
Among the 99 SNPs investigated in stage II, 9 SNPs showed a direction of association consistent with stage I and were further investigated for replication in stage IIIa. Stage IIIa data were extracted from the GWAS data set genotyped by Illumina 660W-Quad from the PECS. We used directly genotyped data for 4 SNPs and used surrogates for the other 5 SNPs (Supplementary Table  S2 ) in an approach similar to that used for stage II. Among these 9 SNPs, 6 SNPs (rs1202529, rs17556883, rs10795561, rs11663212, rs12208947, and rs190262) showed a direction of association consistent with stages I and II and were selected for genotyping in stage IIIb samples. After careful reevaluation of these 6 loci in the Australian/British GWAS data (9), rs9397178 was more significant than the index SNP rs12208947 (P ¼ 0.009 and 0.075, respectively). These 2 SNPs are in strong LD in Asians (r 2 ¼ 0.93) and moderate LD in Caucasians (r 2 ¼ 0.43) based on HapMap data. Similarly, the association of SNP rs1202524 was slightly more significant than rs3828128, a proxy for the index SNP rs1202529 (P ¼ 0.02 and 0.045, respectively). Thus, these 2 SNPs, rs9397178 and rs1202524, were also included in the stage IIIb validation.
Stage IIIb genotyping was conducted by the Sequenom iPLEX MassArray or TaqMan platforms. Genotyping assay protocols were developed and validated at the Vanderbilt Molecular Epidemiology Laboratory. TaqMan genotyping assay reagents were provided to investigators of 3 studies, HAECS, HJCES, and SEARCH. SNP rs450712 was genotyped to serve as a surrogate for the index SNP rs190262 (r 2 ¼ 1.00 in both Asians and Caucasians based on HapMap data) for TaqMan genotyping. Sequenom assay reagents were provided to 5 studies, including the ANECS, BECS, MoMaTEC, NSECG (genotyped in Brisbane), and LES (genotyped in Leuven). Samples from the SECGS-II, CECS, and HECS were genotyped using Sequenom at the Vanderbilt Molecular Epidemiology Laboratory. Another 435 cases from the SECGS-II were genotyped using the same Sequenom SNP pool at Fudan University in Shanghai, China. All studies complied with QC standards by including 2 or more non-DNA template controls per 384-well assay plate, assaying 2% or more duplicate samples, and achieving a genotyping call rate of >95% and concordance rate between duplicate samples of !95% for each SNP assay. Studies with HWE P < 1 Â 10 À4 were automatically excluded from the association analysis. Data for NSECG controls were drawn from the UK1/CORGI colorectal cancer GWAS, which used the Illumina 550K platform (17) . SNPs not on the Illumina 550K were imputed using IMPUTE for the NSECG controls.
Statistical analyses
In stage I, PLINK (version 1.06) was used to analyze the genome-wide data. A set of 4,305 SNPs with a MAF !35% and a distance of !100 kb between 2 adjacent SNPs were selected to evaluate the population structure. The inflation factor l was estimated to be 1.045, suggesting that any population substructure, if present, should not have any appreciable effect on the results.
Associations between SNPs and endometrial cancer risk were assessed using ORs and 95% confidence intervals (CI) derived from logistic regression models. ORs were estimated for heterozygotes and homozygotes for the variant allele compared with homozygotes for the common allele in stage I. ORs were also estimated for the variant allele based on a log-additive model. Meta-analyses for stages II and III were conducted using a weighted average method with the inverse-variance weights, w ¼ 1/se
2 . An overall z-statistic and P value was calculated from the weighted average of the individual statistics. All P values presented are based on 2-tailed tests.
Results
In stage I which was conducted in the Chinese population, multiple genomic locations were revealed as potentially related to endometrial cancer risk ( Supplementary  Fig. S1 ), and the observed number of SNPs with a small P value was larger than that expected by chance (Supplementary Fig. S2) . P values presented in Supplementary  Fig. S1 are derived from trend tests using logistic regression [degrees of freedom (df), 1].
Of the 99 SNPs selected for stage II in silico replication using data from the Australia/British GWAS (9), 13 SNPs had an association with endometrial cancer (P < 0.1) and of these SNPs, 9 had the same direction of association as in stage I (rs10795561, rs11663212, rs1202529, rs12208947, rs12516561, rs17556883, rs190262, rs2876846, and rs4729568; Supplementary Table S3 ). These 9 SNPs were further investigated for replication in the PECS (stage IIIa). Of these, 6 SNPs (rs10795561, rs11663212, rs1202529, rs12208947, rs17556883, and rs190262) had the same direction of association as in stages I and II (Supplementary Table S3 ). After further evaluation of these 6 loci in the stage II data (9), we found that the association for surrogate SNPs rs9397178 and rs1202524 were more significant than the index SNPs rs12208947 and rs1202529. Thus, the 2 surrogate SNPs, rs9397178 and rs1202524, were also included in the stage IIIb validation. Among the 8 SNPs included in the stage IIIb replication, an association was observed for rs1202524 (P ¼ 0.072). The ORs (95% CI) were 1.06 (0.98-1.13) for the A/G genotype and 1.10 (0.97-1.25) for G/G genotype versus A/A (Table  1) . Meta-analyses of all studies combined resulted in a P value of 1.6 Â 10 À4 . Restricting analyses to type I endometrial cancer (endometrioid) cases (7, Table S4 ).
Discussion
In this 3-stage GWAS of endometrial cancer conducted among 8,492 cases and 16,596 controls, we found that SNPs rs1202524 and rs1202529, which are in strong LD, were associated with endometrial cancer risk among both Chinese women and women of European ancestry. Although neither association reached the conventionally used GWAS significance level of 5 Â 10 À8 , the associations were consistent across 9 of 14 contributing studies and did not vary by ethnicity. These 2 SNPs are located on chromosome 1q42.2, approximately 13 and 17 kb downstream of the CAPN9 gene (Fig. 2) . The CAPN9 gene belongs to the calpain gene family, encoding a ubiquitous, well-conserved family of calcium-dependent, cysteine proteases. Multiple, alternatively spliced transcript variants encoding different isoforms have been found for this gene. A growing body of literature has implicated the role of calpain in various aspects of carcinogenesis, including cell-cycle progression, cellular differentiation, and apoptosis (18) . TP53, a substrate of calpains, is known to play an important role in the pathogenesis of various tumors (19) . Inhibitors of calpains have a stabilizing effect on TP53 and can increase TP53 levels and reduce tumor growth. It has been reported that calpain may play an important role in the regulation of estrogen receptor (ER) function. Shiba and colleagues (20, 21) found that calpain activity was significantly higher in breast cancer tissue compared with normal breast tissue, in addition to being higher in ERpositive tumors compared with ER-negative tumors. A very recent study showed that calpain 1, calpain 2, and the inhibitor calpastatin are expressed in endometrial tissue and that endometrial carcinoma has higher expression of calpastatin and calpain 2 than benign endometrial tissue (22) . A number of oncogenic and tumor suppressor proteins are substrates of calpain family enzymes, including c-fos, c-jun, p53, the ER, and integrin (23). Calpain 9, expressed predominantly in the digestive tract, has been associated with suppression of gastric cancer (19) and is downregulated in gastric cancer tissue and both differentiated and poorly differentiated cell lines (24, 25) . It has been suggested that calpain 9 might act as a tumor suppressor through degradation of oncogenic proteins (15).
There exists limited evidence for the functional significance of SNPs rs1202524 and rs1202529. Vasan and colleagues (26) found rs1202524 to be associated with left ventricular diastolic dimension (P ¼ 0.03). Both rs1202529 (27) .
To date, only one SNP (rs4430796) has been identified by a GWAS of endometrial cancer (9) . This SNP is located in the HNF1B gene on chromosome 17q. The per G allele OR (95% CI) was 0.84 (0.79-0.89; P ¼ 7.1 Â 10
À10
). This SNP was not significantly associated with endometrial cancer among Chinese women based on our stage I data (OR per G allele: 0.97; 95% CI, 0.84-1.12), but the direction of the association was consistent with what has been observed among European-ancestry women.
Several limitations of this study should be noted. First, although the present study is one of the largest epidemiologic studies of endometrial cancer, the sample size in the discovery stage is still small and mixed-ethnicity groups were included in the replication study. Unlike the genetic studies of more common cancers, such as the one we conducted on breast cancer (13) , conducting a GWAS of endometrial cancer among Chinese populations alone or even among all Asians is currently unfeasible simply due to the rareness of this cancer and the limited amount of epidemiologic research conducted on it. Therefore, the validation study had to rely mainly on women of European ancestry. Because the allele frequencies of some SNPs differ across populations and LD patterns of adjacent SNPs also vary considerably by population, underlying differences in the genetic architecture of Asian-and European-ancestry populations could have resulted in false-negative results (i.e., failed replication) for some of the 99 SNPs prioritized for replication. Another limitation of this study is that some surrogate SNPs used in the replication stages showed only moderate LD with the index SNPs, which could have reduced the statistical power of the replication study. Nevertheless, finding a consistent association across different populations adds strong evidence for a true association. The lack of direct evidence on the functional significance of the 2 SNPs near the CAPN9 gene is another limitation. Additional functional studies are needed to understand the nature of these SNP associations. Finally, cases with different subtypes of endometrial cancer were included in the present study, which may have biased the results toward the null. In fact, analyses restricted to women with endometrioid histology resulted in more significant associations with the 2 top SNPs.
In summary, in this large GWAS of endometrial cancer, we found one potential locus downstream of the CAPN9 gene associated with endometrial cancer risk. Further research on this genetic region, including functional analyses, would shed light on the biologic role of CAPN9 in endometrial carcinogenesis.
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